Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/7685
Title
Ten years of external quality assessment (EQA) of Neisseria gonorrhoeae antimicrobial susceptibility testing in Europe elucidate high reliability of data
Author(s)
Cole, Michelle J | Quaye, Nerteley | Jacobsson, Susanne | Day, Michaela | Fagan, Elizabeth | Ison, Catherine | Pitt, Rachel | Seaton, Shila | Woodford, Neil | Stary, Angelika | Pleininger, Sonja | Crucitti, Tania | Hunjak, Blaženka | Maikanti, Panayiota | Hoffmann, Steen | Viktorova, Jelena | Buder, Susanne | Kohl, Peter | Tzelepi, Eva | Siatravani, Eirini | Balla, Eszter | Hauksdóttir, Guðrún Svanborg | Rose, Lisa | Stefanelli, Paola | Carannante, Anna | Pakarna, Gatis | Mifsud, Francesca | Cassar, Rosann Zammit | Linde, Ineke | Bergheim, Thea | Steinbakk, Martin | Mlynarczyk-Bonikowska, Beata | Borrego, Maria-José | Shepherd, Jill | Pavlik, Peter | Jeverica, Samo | Vazquez-Moreno, Julio Alberto ISCIII | Abad, Raquel ISCIII | Weiss, Sabrina | Spiteri, Gianfranco | Unemo, Magnus
Date issued
2019-03-25
Citation
BMC Infect Dis. 2019 Mar 25;19(1):281.
Language
Inglés
Document type
journal article
Abstract
BACKGROUND: Confidence in any diagnostic and antimicrobial susceptibility testing data is provided by appropriate and regular quality assurance (QA) procedures. In Europe, the European Gonococcal Antimicrobial Susceptibility Programme (Euro-GASP) has been monitoring the antimicrobial susceptibility in Neisseria gonorrhoeae since 2004. Euro-GASP includes an external quality assessment (EQA) scheme as an essential component for a quality-assured laboratory-based surveillance programme. Participation in the EQA scheme enables any problems with the performed antimicrobial susceptibility testing to be identified and addressed, feeds into the curricula of laboratory training organised by the Euro-GASP network, and assesses the capacity of individual laboratories to detect emerging new, rare and increasing antimicrobial resistance phenotypes. Participant performance in the Euro-GASP EQA scheme over a 10 year period (2007 to 2016, no EQA in 2013) was evaluated. METHODS: Antimicrobial susceptibility category and MIC results from the first 5 years (2007-2011) of the Euro-GASP EQA were compared with the latter 5 years (2012-2016). These time periods were selected to assess the impact of the 2012 European Union case definitions for the reporting of antimicrobial susceptibility. RESULTS: Antimicrobial susceptibility category agreement in each year was ≥91%. Discrepancies in susceptibility categories were generally because the MICs for EQA panel isolates were on or very close to the susceptibility or resistance breakpoints. A high proportion of isolates tested over the 10 years were within one (≥90%) or two (≥97%) MIC log2 dilutions of the modal MIC, respectively. The most common method used was Etest on GC agar base. There was a shift to using breakpoints published by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) in the latter 5 years, however overall impact on the validity of results was limited, as the percentage categorical agreement and MIC concordance changed very little between the two five-year periods. CONCLUSIONS: The high level of comparability of results in this EQA scheme indicates that high quality data are produced by the Euro-GASP participants and gives confidence in susceptibility and resistance data generated by laboratories performing decentralised testing.
Subject
MESH
Anti-Bacterial Agents | Disk Diffusion Antimicrobial Tests | Drug Resistance, Bacterial | Europe | Laboratories | Microbial Sensitivity Tests | Neisseria gonorrhoeae | Quality Control | Reproducibility of Results
Online version
DOI
Collections